Forte Biosciences (FBRX) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. NDAQ

Go back to Forte Biosciences (FBRX) Misses Q2 EPS by 4c

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

August 15, 2022 4:05 PM EDT

-Forte Biosciences is Developing a Novel Pipeline for the Treatment of Autoimmune Diseases-

-Leadership Strengthened with Appointments of Hubert Chen, M.D. as Chief Scientific Officer and Stephen Doberstein, Ph.D. to the Board of Directors-

-Ended second quarter 2022 with approximately $38.5 million in cash and cash equivalents-

DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc.... More